Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

A wearable high-density electromyography system for real-world monitoring and diagnosis of Parkinson’s disease

Project description

Wearable device for Parkinson’s disease diagnosis and monitoring

Parkinson’s disease (PD) is difficult to diagnose and monitor. Current clinical practices rely on subjective evaluations, limiting the accurate tracking of progression and the delivery of personalised therapies. The ERC-funded ParkEMG project aims to develop a wearable platform that can track and monitor relevant neural activity from the motor nervous system in a continuous way. Combining High-Density Electromyography (HD-EMG) and inertial sensing, this device will focus on capturing essential neural information underlying PD rather than just its external symptoms. The project seeks to quantify cortico-muscular activity in the beta frequency band and relevant movement biomarkers, such as bradykinesia and tremor, offering insights into PD pathophysiology. Development will involve hardware miniaturisation, firmware and algorithm enhancements, and pilot testing with healthy volunteers and PD patients.

Objective

Parkinson’s disease (PD) affects over 10 million people worldwide and remains one of the most challenging neurological disorders to diagnose and monitor. Current clinical practice relies mainly on subjective evaluations and indirect measures, which limits accurate tracking of disease progression and the development of personalized therapies. There is a clear unmet need for objective, reliable, and user-friendly biomarkers that can be measured in real-world conditions. This Proof of Concept develops ParkEMG, an intelligent wearable platform conceived as the first “Holter for the motor nervous system.” The device integrates High-Density Electromyography (HD-EMG) and inertial sensing with embedded intelligence. This dual-sensor strategy records relevant neural information underlying the pathological condition, instead of focusing on its external motor manifestations. Building on ERC-funded advances in neural decoding, ParkEMG will focus on quantifying cortico-muscular activity in the beta band and movement biomarkers such as bradykinesia and tremor, offering new windows into PD pathophysiology. The project will advance through hardware miniaturization, firmware and algorithm development, pilot validation in healthy volunteers and PD patients, and an iterative design cycle toward a minimum viable product. In parallel, structured market and IP assessments will guide exploitation. By bridging cutting-edge neurotechnology with real-world usability, ParkEMG could enable more reliable and faster diagnosis of PD, objective monitoring, and more effective treatment, ultimately improving quality of life for millions of patients.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

UNIVERSIDAD DE ZARAGOZA
Net EU contribution
€ 150 000,00
Address
CALLE PEDRO CERBUNA 12
50009 Zaragoza
Spain
Region
Noreste Aragón Zaragoza
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)